It seems like that's par for the course anymore on any stock now- any bad news and it plunges. Way overdone selloff . The other problem is the 'yearly dividend' - I think a quarterly one would keep the share value more stable. MDVN take over attempt also was viewed negative - since the street thinks SNY will eventually 'overpay'' for it - if they do indeed get it. The future looks bright, though - their pipeline is strong along with the Boeringer asset swap at end of year. They are getting stronger in emerging markets as well (expanding in China). Before you 'dump' you should do a little more research- since I think they will firm up again as year goes on.
This has been awful.....bot at 51, as SNY was moving up, and then they warned and instantly to 47, then lower and lower.....a rise to 44.50 and then 39.....the pain is bad......I will never buy an ADR again.....anyone else there? Anyone else going thru this?
ULTIMATESTOCKALERTS is the best service I have found so far. Their alerts kill it for me, I Doubled my account in 2015 in part to them, Hope to do it again this year.
Mylan is slowly building its global war chest and will earn profits at the lowest tax rate! Their inversion worked, and they made smart moves to buy Abbot LAbs euro generic business while recently adding others!! It is time for Sanofi to step to the plate or be left behind!
Ha Ha - you are on 'deaf ears' here- 95% of MDVN is owned by institutions- you should petition them!
Now it's MDVN and I hope all Companies will avoid SNY as partner!
They should all use a Poison pill share policy
Most analysts are pricing it around $70 now on the buyout. The 'whole sector' is really undervalued with the sale-off mainly due to 'saber rattling' in Washington. If you don't want to take single stock risk with MDVN - it might be worth 'buying the sector' via an ETF. Sanofi should start to come around by the end of year when 3- new drugs come on line and the Boehringer asset swap is completed. Again- they might end up with MDVN- but that is still a 'roll of the dice'.
Must be 'sale in May and go away syndrome'. There is a lot of value in the whole group- SNY looks totally oversold here- buy it down here for a great 17'!
Just read that Barclays up-graded to 'Overweight' - not concerned about Praluent's effect on future revenue growth (minimal).
Although SNY was not mentioned in report- I imagine it will be 'market perform'. I do not think it is on 'Radar' yet - since it is just starting to 'restructure'. ! Start accumulating it now for a nice total return !
I checked - and sales volume is 'paltry' at 104 million. A patent infringement lawsuit won by Amgen is under appeal which if not overturned could result in 'royalties' of 5-10%* having to be paid by Regeneron/Sanofi on sales (*This based on similar settlements).
This might be a plus- since better pricing might be made up in 'better volume' since insurers of course reject prescriptions into the 'high priced' meds unless deemed necessary.
The sourced article doesn't necessarily exclude Sanofi as the new articles I'm reading state Pfizer and Amgen are among those signing NDAs.
In other news, MDVN has NDAs with Pfizer and Amgen. Looks like they'll get an in depth look at the financials not offered to Sanofi in order to really find out what this is worth.